Tissue Regenix Group Plc (TRX) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.007x

Based on the latest financial reports, Tissue Regenix Group Plc (TRX) has a cash flow conversion efficiency ratio of -0.007x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-202.00K ≈ $-24.58 USD) by net assets (GBX28.62 Million ≈ $3.48K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TRX defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Tissue Regenix Group Plc - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Tissue Regenix Group Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Tissue Regenix Group Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tissue Regenix Group Plc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Ordinary Fully Paid Deferred Settlement AU:GMNDA	N/A
Shapeways Holdings, Inc NASDAQ:SHPWQ	-0.202x
Meta Materials Inc. NASDAQ:MMATQ	-0.323x
Accentro Real Estate AG F:A4Y	0.064x
H C Slingsby PLC LSE:SLNG	0.086x
Hempacco Co., Inc. NASDAQ:HPCO	1.120x
Edgio, Inc. NASDAQ:EGIOQ	-0.070x
Isomet Corp NASDAQ:IOMT	0.073x

Annual Cash Flow Conversion Efficiency for Tissue Regenix Group Plc (2008–2024)

The table below shows the annual cash flow conversion efficiency of Tissue Regenix Group Plc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see Tissue Regenix Group Plc stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	GBX29.06 Million ≈ $3.54K	GBX-1.64 Million ≈ $-198.93	-0.056x	-258.83%
2023-12-31	GBX29.36 Million ≈ $3.57K	GBX1.04 Million ≈ $126.54	0.035x	+169.20%
2022-12-31	GBX25.27 Million ≈ $3.08K	GBX-1.29 Million ≈ $-157.44	-0.051x	+57.57%
2021-12-31	GBX24.65 Million ≈ $3.00K	GBX-2.98 Million ≈ $-361.97	-0.121x	+44.50%
2020-12-31	GBX27.85 Million ≈ $3.39K	GBX-6.05 Million ≈ $-736.72	-0.217x	+24.13%
2019-12-31	GBX24.59 Million ≈ $2.99K	GBX-7.05 Million ≈ $-857.66	-0.287x	-37.96%
2018-12-31	GBX32.57 Million ≈ $3.96K	GBX-6.77 Million ≈ $-823.23	-0.208x	+16.10%
2018-01-31	GBX39.52 Million ≈ $4.81K	GBX-9.79 Million ≈ $-1.19K	-0.248x	-0.48%
2017-12-31	GBX39.52 Million ≈ $4.81K	GBX-9.74 Million ≈ $-1.18K	-0.246x	+73.43%
2016-12-31	GBX11.54 Million ≈ $1.40K	GBX-10.70 Million ≈ $-1.30K	-0.927x	-121.78%
2016-01-31	GBX30.25 Million ≈ $3.68K	GBX-12.65 Million ≈ $-1.54K	-0.418x	+40.36%
2015-01-31	GBX11.58 Million ≈ $1.41K	GBX-8.12 Million ≈ $-987.60	-0.701x	-135.61%
2014-01-31	GBX31.30 Million ≈ $3.81K	GBX-9.31 Million ≈ $-1.13K	-0.298x	-77.43%
2013-01-31	GBX38.64 Million ≈ $4.70K	GBX-6.48 Million ≈ $-788.51	-0.168x	-119.91%
2012-01-31	GBX43.78 Million ≈ $5.33K	GBX-3.34 Million ≈ $-406.19	-0.076x	+67.87%
2011-01-31	GBX9.84 Million ≈ $1.20K	GBX-2.34 Million ≈ $-284.20	-0.237x	-139.99%
2010-01-31	GBX3.67 Million ≈ $446.11	GBX-362.65K ≈ $-44.12	-0.099x	+29.53%
2009-01-31	GBX3.63 Million ≈ $442.27	GBX-510.22K ≈ $-62.08	-0.140x	-144.13%
2008-01-31	GBX9.68 Million ≈ $1.18K	GBX-556.78K ≈ $-67.74	-0.057x	--

About Tissue Regenix Group Plc

LSE:TRX UK Biotechnology

Market Cap

$628.37

GBX5.16 Million GBX

Market Cap Rank

#31732 Global

#1314 in UK

Share Price

GBX0.07

Change (1 day)

+0.00%

52-Week Range

GBX0.07 - GBX39.00

All Time High

GBX2162.50